Host immunosurveillance controls tumor growth via IFN regulatory factor-8-dependent mechanisms

Cancer Research

Volumn 67, Issue 21, 2007, Pages 10406-10416

  Greeneltch, Kristy M ^a   Schneider, Monika ^a   Steinberg, Seth M ^a   Liewehr, David J ^a   Stewart, Trina J ^a   Liu, Kebin ^b   Abrams, Scott I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MOUSE; MYELOPOIESIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FAS LIGAND PROTEIN; FEMALE; IMMUNITY, NATURAL; INTERFERON REGULATORY FACTORS; INTERFERON TYPE II; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TUMOR ESCAPE;

EID: 35948988088     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1228     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res 1996;56:4791-8.
3. Krammer PH, Galle PR, Moller P, Debatin KM. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res 1998;75:251-73.
4. Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL. Fas and Fas ligand interactions in malignant disease. Int J Oncol 2000;17:5-12.
5. Yamana K, Bilim V, Hara N, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005;93:544-51.
6. Zhang Z, Wang LE, Sturgis EM, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006; 12:5596-602.
7. Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170:6338-47.
8. Liu K, Abrams SI. Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 2003;170: 5973-80.
9. Liu K, Caldwell SA, Abrams SI. Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. Cancer Res 2005;65:1045-54.
10. Lee JK, Sayers TJ, Brooks AD, et al. IFN-γ-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000;164:231-9.
11. Siegmund D, Wicovsky A, Schmitz I, et al. Death receptor-induced signaling pathways are differentially regulated by γ interferon upstream of caspase 8 processing. Mol Cell Biol 2005;25:6363-79.
12. Wigginton JM, Gruys E, Geiselhart L, et al. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51-62.
13. Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI. CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 2006; 176:3374-82.
14. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997;8:293-312.
15. Tamura T, Ozato K. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res 2002;22:145-52.
16. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 2000;13:155-65.
17. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87:307-17.
18. Gabriele L, Phung J, Fukumoto J, et al. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 1999;190:411-21.
19. Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J Immunol 2003;170: 6329-37.
20. Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 2003;171:2402-12.
21. Smyth MJ, Thia KY, Cretney E, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 1999;162:6658-62.
22. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-63.
23. Giagkousiklidis S, Vogler M, Westhoff MA, et al. Sensitization for γ-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 2005;65:10502-13.
24. Krueger SA, Joiner MC, Weinfeld M, Piasentin E, Marples B. Role of apoptosis in low-dose hyperradiosensitivity. Radiat Res 2007;167:260-7.
25. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002;2:139-48.
26. Tseng JC, Levin B, Hirano T, et al. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 2002; 94:1790-802.
27. McMillan TJ, Rao J, Everett CA, Hart IR. Interferon-induced alterations in metastatic capacity, class-1 antigen expression and natural killer cell sensitivity of melanoma cells. Int J Cancer 1987;40:659-63.
28. Roder JC. The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function. J Immunol 1979;123:2168-73.
29. Smyth MJ, Swann J, Hayakawa Y. Innate tumor immune surveillance. Adv Exp Med Biol 2007;590:103-11.
30. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
31. Driggers PH, Ennist DL, Gleason SL, et al. An interferon γ-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1990;87:3743-7.
32. Weisz A, Marx P, Sharf R, et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 1992;267:25589-96.
33. Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol 1993;13:588-99.
34. Burchert A, Cai D, Hofbauer LC, et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood 2004;103:3480-9.
35. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000;20:1149-61.
36. Turcotte K, Gauthier S, Tuite A, et al. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med 2005;201:881-90.
37. Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 2007;67:3301-9.
38. Egwuagu CE, Li W, Yu CR, et al. Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 2006; 25:3670-9.
39. Fanzo JC, Hu CM, Jang SY, Pernis AB. Regulation of lymphocyte apoptosis by interferon regulatory factor 4 (IRF-4). J Exp Med 2003;197:303-14.
40. Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005;54:1137-42.
41. Lum HD, Buhtoiarov IN, Schmidt BE, et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 2006;79: 1181-92.
42. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
43. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
44. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995;166:236-46.
45. Seki N, Brooks AD, Carter CR, et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002;168:3484-92.
46. Cappello P, Novelli F, Forni G, Giovarelli M. Death receptor ligands in tumors. J Immunother 2002;25:1-15.
47. Chauhan P, Sodhi A, Tarang S. Cisplatin-treated murine peritoneal macrophages induce apoptosis in L929 cells: role of Fas-Fas ligand and tumor necrosis factor-tumor necrosis factor receptor 1. Anticancer Drugs 2007;18:187-96.